PCSK9 Antibodies

Santa Cruz Biotechnology features a diverse variety of PCSK9 monoclonal antibodies for research focused on proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism and cardiovascular health. PCSK9 Antibodies are validated for multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA).PCSK9 is a key regulator of cholesterol homeostasis, primarily by modulating the degradation of low-density lipoprotein receptors (LDLR) in the liver. The significance of PCSK9 in cardiovascular disease has established it as a target for therapeutic intervention, with PCSK9 inhibitors demonstrating success in lowering LDL cholesterol levels and reducing cardiovascular events. Understanding PCSK9 function and regulation continues to be essential for developing effective treatments for hypercholesterolemia and related disorders. Research utilizing PCSK9 monoclonal antibodies has revealed important insights into cholesterol metabolism pathways. Investigating PCSK9 expression patterns helps identify potential therapeutic approaches for cardiovascular conditions. Current studies focusing on PCSK9 are uncovering new aspects of lipid regulation and transport. Santa Cruz Biotechnology monoclonal antibodies enable researchers to advance scientific understanding of cardiovascular health and disease mechanisms.